Results per Page:
50 years of doing hard things
Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution
Anti-(idio)typical: a new immunogen to vaccinate against RSV
From the McGuire Lab, Vaccine & Infectious Disease Division
How protective antibodies get in malaria’s way
Fred Hutch researchers’ structural insights help reveal weak spot in parasite’s mode of attack, could guide vaccine design
Vaccine targets that accommodate evolving SARS-CoV-2 variants
From the Overbaugh Lab, Human Biology and Public Health Sciences Divisions
Getting a paw up in the cat-and-mouse game with the COVID-19 virus
Fred Hutch researchers invent method to quickly and safely test thousands of mutations to predict which ones could help the virus escape our defenses
A promising HIV vaccine candidate gets a little help
New strategy stirs a robust response from T cells tracked by McElrath lab
Beyond aesthetics: a visualization tool for better vaccines
From the Bedford lab, Vaccine and Infectious Disease Division
Fred Hutch leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
Meta-analysis of 122 COVID-19 clinical trials cites need for strategies to address trial participation gaps
On World AIDS Day, a broad view of continuing work
Teams of Fred Hutch scientists test vaccines, treatments, new strategies
Dr. Larry Corey receives Alexander Fleming Award
Virologist honored by peers for his lifetime achievements against infectious diseases
Latest Fred Hutch research on COVID-19
How Hutch scientists have been tackling coronavirus in lab and clinic
Test of a new 'germline-targeting' HIV vaccine prepares to launch
Vaccine’s unique protein designed to start process of building powerful antibodies against AIDS virus
What Hutch coronavirus experts are saying about omicron
Some answers, but many questions, about highly mutated new variant of COVID-19 virus
IAVI and Moderna launch trial of HIV vaccine antigens delivered through mRNA technology
Phase 1 trial aims to build on response seen in proof-of-concept trial
Hopes and predictions for 2022
Hutch researchers look ahead to an increase in cancer screening, improved vaccines and greater trust in science
Highlights of Fred Hutch science in 2021
From COVID-19 to cancer, Hutch scientists pursued new ideas to save lives
World AIDS Day 2021: Let's give the gifts of hope and focus to HIV research
HIV scientific infrastructure paved the way for the world’s COVID-19 response. Now, it’s time to return the favor.
Community engagement ensures equitable inclusion in vaccine trials
New study from COVID-19 Prevention Network demonstrates impacts of engaging Black, Indigenous, people of color communities
Science Says: Back to the future
Navigating work, school, and well-being in a world transformed by COVID-19